Results 221 to 230 of about 5,130,717 (259)
Some of the next articles are maybe not open access.
Journal of Gastroenterology and Hepatology, 1996
Abstract Primary sclerosing cholangitis is rare among Chinese. We report on a 71 year old male patient who presented with clinical features consistent with the disorder. Subsequent investigations confirmed the diagnosis. The patient was found to have anti‐neutrophil cytoplasmic antibodies with specificity against proteinase 3.
SAI SIONG WONG, JWM LAWTON
openaire +2 more sources
Abstract Primary sclerosing cholangitis is rare among Chinese. We report on a 71 year old male patient who presented with clinical features consistent with the disorder. Subsequent investigations confirmed the diagnosis. The patient was found to have anti‐neutrophil cytoplasmic antibodies with specificity against proteinase 3.
SAI SIONG WONG, JWM LAWTON
openaire +2 more sources
European Journal of Clinical Investigation, 2021
The prognosis of primary bile cholangitis (PBC) is linked to gut microbiota dysbiosis. This study investigated the association between the gut microbiome and elevated total bilirubin (TB) level in PBC patients treated with ursodeoxycholic acid (UCDA).
W. Han +9 more
semanticscholar +1 more source
The prognosis of primary bile cholangitis (PBC) is linked to gut microbiota dysbiosis. This study investigated the association between the gut microbiome and elevated total bilirubin (TB) level in PBC patients treated with ursodeoxycholic acid (UCDA).
W. Han +9 more
semanticscholar +1 more source
Alimentary Pharmacology and Therapeutics, 2021
Ursodeoxycholic acid (UDCA) is the first‐line therapy for primary biliary cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA. The addition of bezafibrate has shown biochemical benefit in this group of patients.
J. Sordá +6 more
semanticscholar +1 more source
Ursodeoxycholic acid (UDCA) is the first‐line therapy for primary biliary cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA. The addition of bezafibrate has shown biochemical benefit in this group of patients.
J. Sordá +6 more
semanticscholar +1 more source